Skip to main content
Lytix Biopharma AS logo

Lytix Biopharma AS — Investor Relations & Filings

Ticker · LYTIX ISIN · NO0010405780 LEI · 549300NXMIMRSBCDZO71 OL Manufacturing
Open in API
Filings indexed 279 across all filing types
Latest filing 2026-05-15 Report Publication Anno…
Country NO Norway
Listing OL LYTIX

About Lytix Biopharma AS

https://www.lytixbiopharma.com/

Lytix Biopharma AS is a clinical-stage immuno-oncology company that develops a proprietary platform of oncolytic molecules for cancer treatment. The company's technology is based on molecules designed to selectively target and lyse cancer cell membranes. This process releases a broad spectrum of tumor antigens, which in turn stimulates a patient's immune system to recognize and attack the cancer, effectively turning immunologically "cold" tumors "hot". Its lead drug candidate, ruxotemitide, is being evaluated in clinical trials as a neoadjuvant treatment for various solid tumors, including melanoma and basal cell carcinoma.

Recent filings

Filing Released Lang Actions
Lytix Biopharma: Invitation to the Q1 2026 Results Presentation
Report Publication Announcement Classification · 86% confidence The document is a press release inviting investors to a live webcast presentation of the company’s upcoming Q1 2026 financial results. It does not contain any actual financial data or the full presentation itself, but rather announces the timing, format, and access details for the report release. Under the “menu vs. meal” rule, this is an announcement regarding the publication/timing of a report, not the report itself.
2026-05-15 English
New Phase II Study Data from Lytix Biopharma’s Partner Verrica Pharmaceuticals to be Presented at SID 2026 Highlight Potential Abscopal Effects of Ruxotemitide in Basal Cell Carcinoma
Regulatory Filings
2026-05-06 Norwegian
Lytix Biopharma ASA to Showcase Promising Phase II Results for Ruxotemitide Combination Therapy at ASCO 2026
Regulatory Filings Classification · 65% confidence The document is a short press release announcing Phase II trial results being presented at the ASCO conference. It does not contain financial results, governance changes, management discussion, or detailed investor materials, nor is it a formal report or regulatory filing like a 10-K or interim report. It is not announcing a shareholder vote, dividend, or financing, but rather a scientific presentation. This does not match any specific category except as a general announcement. Therefore, it falls into the fallback category of Regulatory Filings (RNS).
2026-04-21 English
Lytix Biopharma ASA Reports Promising Final Phase II Results for Ruxotemitide (LTX-315) in Combination with Pembrolizumab in PD-1/PD-L1 Refractory Advanced Melanoma - Attachment: Lytix_AACR Poster_Fin
Regulatory Filings Classification · 20% confidence The document is a clinical research poster (AACR Annual Meeting 2026) presenting trial methods, results, tables of efficacy and safety for an intratumoral therapy in melanoma. It is not a corporate financial filing, earnings release, management presentation, regulatory notice, or any of the defined corporate disclosure types. It does not announce dividends, share transactions, board changes, or financial results in a corporate context. Therefore it does not fit any specific category and is classified as a fallback Regulatory Filing (RNS).
2026-04-21 English
Lytix Biopharma ASA Reports Promising Final Phase II Results for Ruxotemitide (LTX-315) in Combination with Pembrolizumab in PD-1/PD-L1 Refractory Advanced Melanoma
Regulatory Filings Classification · 40% confidence The document is a corporate press release announcing final Phase II clinical trial results for a cancer therapy. It is not an annual or interim financial report, earnings release, management change, dividend notice, or any of the specific categories provided. It is a miscellaneous regulatory announcement of corporate clinical data and thus falls into the fallback category ‘Regulatory Filings’ (RNS).
2026-04-21 English
Lytix Biopharma ASA – Conversion to public limited liability company and name change registered
Regulatory Filings Classification · 75% confidence The document is a short stock exchange announcement regarding Lytix Biopharma’s conversion from a private limited company (AS) to a public limited company (ASA) and a name change. It contains no financial results, no meeting minutes, no shareholder vote details, and no detailed report attached—only a corporate action disclosure. This does not fit specific categories like share issue (SHA) or governance rules (CGR), so it falls into the fallback “Regulatory Filings” category (RNS).
2026-04-16 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.